According to reports from CNBC TV18, Metropolis Healthcare delivered robust first-quarter results for FY27, with consolidated net profit rising 26% year-on-year to ₹57 crore compared with ₹45 crore in the corresponding period last year. Revenue from operations increased 17% to ₹450 crore from ₹386 crore a year earlier, while EBITDA grew 27% year-on-year to ₹113 crore with a margin of 25.2%. The company's EBITDA margin expanded to 48.3% from 46.1% in the year-ago period, indicating strong operating leverage benefits from higher patient and test volumes.
As reported by CNBC TV18, Metropolis Healthcare achieved patient volumes growth of 10% year-on-year and test volumes growth of 11% during the quarter. The company attributed this growth to sustained demand, deeper market penetration, and the continued shift towards organised diagnostic chains. The diagnostics sector has been gradually moving away from fragmented local laboratories towards branded chains, as consumers increasingly prioritise reliability, quality standards and faster digital access to reports. The faster EBITDA growth compared to revenue growth demonstrates the company's ability to improve profitability without proportional increases in costs.
According to CNBC TV18, Metropolis Healthcare continued to see strong growth in its specialised diagnostic offerings. Revenue from TruHealth increased 22% year-on-year to ₹81 crore, contributing around 18% of total revenue, while Specialty Diagnostics revenue rose 17% to ₹178 crore, accounting for around 40% of the revenue mix. Premium TruHealth packages grew by more than 50%, while radiology-integrated wellness packages expanded over 40%. The growth in premium health packages reflects a broader consumer shift towards preventive healthcare, where customers increasingly opt for regular screenings and comprehensive health checks rather than only seeking diagnosis after illness.
As reported by Mint, Metropolis Healthcare saw particularly strong momentum in tier-III markets, where revenue increased around 25-26% during the quarter, significantly higher than growth in Tier I cities at 11% and Tier II cities at 14%. About 27-28% of Metropolis's business now comes from tier-III towns and beyond, with the company adding 70-75 labs in smaller towns over the past three years. Managing Director Surendran Chemmenkotil noted that the tier-III expansion reflects a two to three year investment journey in these markets, as the company educates doctors about specialized tests and creates new demand through organized player capabilities. Executive Chairperson Ameera Shah emphasized that this strategy is not just capturing market share from unorganized providers but actively creating new demand, as local laboratories lack the capability to perform specialized tests.
According to Mint, Metropolis Healthcare is now prioritizing network density over aggressive expansion, focusing on adding collection centres, partnering with smaller labs and hospitals, and deepening reach in existing markets. The company has acquired four assets over the past two years to strengthen its foothold in Maharashtra and north India, following aggressive organic expansion that established 90 labs serving around 750 towns. Despite significant headroom for growth, with organized players accounting for just 15% of India's diagnostics market and listed companies holding roughly 10% share, the company remains open to strategic acquisitions that expand geographic footprint or add niche capabilities. India's diagnostics market was worth $11 billion in 2025 and is projected to expand at 11% compound annual growth rate until 2034.
